CD24+/CD38- as new prognostic marker for non-small cell lung cancer by Feridoun Karimi-Busheri et al.
Karimi-Busheri et al. Multidisciplinary Respiratory Medicine 2013, 8:65
http://www.mrmjournal.com/content/8/1/65ORIGINAL RESEARCH ARTICLE Open AccessCD24+/CD38- as new prognostic marker for
non-small cell lung cancer
Feridoun Karimi-Busheri1,2*, Aghdass Rasouli-Nia2, Victoria Zadorozhny1 and Habib Fakhrai1Abstract
Background: Lung cancer is the leading cause of death among cancers in the world. The annual death toll due to
this disease exceeds the combined deaths caused by colon, breast, prostate, and pancreatic cancers. As a result,
there has been a tremendous effort to identify new biomarkers for early detection and diagnosis of lung cancer.
Methods: In this study we report the results of screening a panel of eight non-small cell lung cancer (NSCLC) cell
lines originating from different subtypes of lung cancer in an attempt to identify potential biomarkers unique to
this disease. We used real-time polymerase chain reaction and flow cytometry techniques to analyze the expression
of ALDHA1, EpCAM, CD133, CD24, and CD38 in this panel.
Results: We demonstrate for the first time that the majority of NSCLC cells do not express levels of CD38 that
would qualify it as a new biomarker for the disease. In contrast, we found that CD24 is over-expressed in 6 out of 8
of the cell lines. The combined CD24+/CD38-/low phenotype was detected in 50% of the cell lines that are also
positive for CD133 and EpCAM.
Conclusions: We report that CD24+/CD38-/low signature could potentially be used as a new biomarker for the early
detection of NSCLC.
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Despite being the number one killer among all cancers,
potent biomarkers that can efficiently target a significant
number of lung tumor cells are far from having any
impact in prognosis and diagnostics of this malignancy.
The five-year survival rate of all patients is only 15% and
has not changed over the last thirty years [1]. According
to an estimate in 2007, the cost of detection and treatment
of lung cancer in the United States alone has been over
$5 billion dollars per year [2]; absorbing 20% of Medicare’s
total expenditures for cancer [3]. There is an intense effort
underway globally to identify new molecular markers
for Non-small cell lung cancer (NSCLC), in particular
molecular biomarkers for the early detection as late stage
lesions are strongly associated with high mortality [4,5].
It is expected that future genetic markers together with
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distribution, and reproduction in any mediumsignificantly improve the prognosis of NSCLC and influ-
ence treatment decision [6]. The emergence of the “-omics”
era will likely revolutionize our approach towards the
discovery of biomarkers. Genomics, epigenomics, and pro-
teomics are among the new technologies that have identi-
fied potential next-generation biomarkers [7]. Analysis
of microRNAs (miRNAs) and DNA methylation have led
to the identification of many promising biomarkers that
when integrated with other potential biomarkers could be
used for the early detection of high risk lung cancer
patients [4,8]. In a different study, proteomics analysis
of NSCLC has led to the identification of two new proteins,
PTRF/cavin-1 and MIF, as potential therapeutic targets [9].
The expression of aldehyde dehydrogenase A1 (ALDHA1)
in tumor cells is the focus of attention both in diagnostic
and therapeutic settings [10]. ALDH is an intracellular
enzyme involved in metabolism of various molecules within
cells such as retinoic acid, alcohol, cyclophosphamide,
oxidative stress response, and aldehyde produced during
lipid metabolism [11,12]. It has been reported that the
enzyme is highly expressed in some of the NSCLC cellCentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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Karimi-Busheri et al. Multidisciplinary Respiratory Medicine 2013, 8:65 Page 2 of 9
http://www.mrmjournal.com/content/8/1/65lines and also in the patient’s specimen [12,13]. Although
little is known about epithelial cell adhesion molecule
(EpCAM) gene expression in NSCLC, a few studies have
reported the upregulation of EpCAM in NSCLC cell lines
and specimens, notably in squamous cell carcinoma
[14-16]. CD133, a transmembrane glycoprotein, has been
reported to be one of the most representative markers
of tumor initiating cells in various tumors such as glio-
blastoma and colorectal carcinoma [17,18]. The analysis
of CD133 expression in stage I lung adenocarcinoma
tumors has revealed an association with disease recur-
rence and led to the proposal that CD133 could be
used as an independent prognostic marker [19]. In the
last few years, increasing evidence has shed light on the
importance of CD24 as a potent prognostic marker in
breast, ovarian, NSCLC, and prostate cancers [5,20-22]. In
a previous study, we have shown that expression of the
cell surface protein CD38 is higher in cancer stem cells
isolated from the H460 NSCLC [23,24]. This is a multi-
functional enzyme involved in cell adhesion, signal trans-
duction, and as a receptor in cells of the immune system
[25]. CD38 contribution to disease progression and re-
lapse in acute myeloid leukaemia and chronic lympho-
cytic leukemia is well established and the expression
of the enzyme is considered an important prognostic
marker in leukemia [26-28]. In the current study we have
assessed the validity of some of the most discussed potential
biomarkers of NSCLC, including CD38, in a panel of lung
cancer cell lines in search of potent prognostic markers
and signature phenotypes for NSCLC.
Methods
Material, cell lines, and culture media
All the cell lines (H460, A549, H661, H292, SW-900,
SK-MES, H596, and H520) were purchased from the
American Type Culture Collection (ATCC, Rockville, MD).
Cells were cultured and grown in media according to
ATCC recommendation. Dulbecco’s Modified Eagle
Medium/F12 (DMEM/F12) was obtained from SAFC
Biosciences (Lenexa, KS), B27 serum-free supplements
and penicillin/streptomycin were purchased from Life
Technologies (Carlsbad, CA), sodium bicarbonate and
sodium pyruvate were obtained from VWR (West Chester,
PA), basic fibroblast growth factor was purchased from
Millipore Inc. (Billerica, MA). Tissue culture suspension
plates and flasks were purchased from Sarstedt Inc.
(Newton, NC), and BioCoat collagen I coated plates
from BD Biosciences (San Jose, CA). ALDEFLUOR Assay
Kit was obtained from Stem Cell Technologies Inc.
(Vancouver, BC). Mouse anti-human CD24 phycoerythrin-
conjugated (PE) was purchased from BD Biosciences Inc.
(San Jose, CA), PE anti-human CD326 (EpCAM) and PE
anti-human CD38 antibody from Biolegend (San Diego,
CA), and mouse anti-human CD133/1 (AC133)-PE andCD133/2 from Miltenyi Biotec (Auburn, CA). All other
chemicals were purchased from Sigma-Aldrich (St. Louis,
MO) unless noted otherwise.
Flow cytometry analysis
Enriched populations of lungospheres were analyzed by
flow cytometry as described earlier [23,24]. Briefly, after
trypsinization and washing the cells with medium, 1 × 106
cells were passed through 0.45 μM filters to remove clumps
of cells followed by washing with FACS buffer (phosphate
saline buffer, 2% fetal bovine serum, and 2 mM ethylenedi-
aminetetraacetic acid (EDTA)). Cells were centrifuged at
1,200 rpm for five minutes and the cell pellet was re-
suspended in 100 μl FACS buffer containing 20 μl of CD24,
CD38, or EpCAM antibodies. After incubation for 20 mi-
nutes on ice in the dark, cells were washed twice with 2 ml
of FACS buffer and after the final wash they were re-
suspended in 200–500 μl of FACS buffer. Cells were kept on
ice/dark prior acquisition on Attune Acoustic Focusing from
Applied Biosystems (Carlsbad, CA). As negative control, an
isotype-matched labeled control was used for each antibody.
Aldefluor assay
Aldefluor assay was performed according to the manu-
facturer instruction. Two sets of tubes were labeled as
sample and control for each cell line to be tested. To the
sample tube, 1 × 106 cells were added and to the control
tube 5 μl of diethylaminobenzaldehyde (DEAB), a specific
ALDH inhibitor. Cells in the sample tube were mixed with
5 μl of activated ALDEFLUOR and 0.5 ml of the mixture
was transferred to the control tube containing DEAB.
Tubes were vortexed and incubated at 37°C for 30 min.
Pelleted cells after centrifugation at 1000 rpm for 5 min
were resuspended in 500 μl aldefluor assay buffer and
analyzed on an Attune flow cytometer.
Real-time reverse transcriptase-PCR
RNA was isolated from 5 × 106 cells using Absolutely
RNA Miniprep kit (Stratagene) according to manufacturer’s
recommendations. The cDNA was synthesized by using
Transcriptor First Strand cDNA Synthesis Kit (Roche
Applied Science, Indianapolis, IN) from 0.5 μg of total
RNA. RNA was incubated with anchored-oligo(dT)18
primer for 10 min at 65°C to denature template-primer
mixture and chilled on ice. 5× reaction buffer, RNase
inhibitors, 10 mM dNTPs mix and transcriptor reverse
transcriptase were added to the reaction mixture and
incubated at 50°C for 60 min, followed by 85°C for
5 min to inactivate reverse transcriptase and chilled on ice.
Real-time PCR was performed using LightCycler 480
and LightCylcer 480 SYBR Green I Master (Roche
Applied Science). Master mixture containing cDNA,
Syber Green Master and 100 μM forward and reverse
primers were prepared on ice (Table 1). RT-PCR was
Table 1 Primer used for RT-PCR
Gene Accession Forward primer Reverse primer
CD24 NM_013230 CACGCAGATTTATTCCAGTGAAAC GACCACGAAGA GACTGGCTGTT
CD38 NM_001775 TCTTGCCCAGACTGGAGAAAGG TGGACCACATCACAGGCAGCTT
GAPDH AF261085 ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA
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followed by 45 cycles of denaturation at 95°C for 10 sec,
annealing at 60°C for 20 sec, and elongation at 72°C for
18 sec. To ensure that the expected PCR products were
generated, melting curves were also analyzed. Relative
mRNA expression levels were obtained by normalizing
the amount of mRNA divided by that of GAPDH mRNA
as an endogenous control in each sample.Figure 1 Aldehyde dehydrogenase 1A (ALDH1) expression among the
of ALDH is used as negative control.Results
Assurance of cell line identification
The authenticity of all eight NSCLC lines used in this
study were validated by short tandem repeated DNA se-
quence (STR) as described earlier [23]. Briefly, DNA was
extracted from the cell lines and amplified by PowerPlex
1.2 System (Promega, Madison WI) according to manu-
facturer instructions. The data then were analyzed oneight non-small cell lung carcinoma cell lines. DAEB, an inhibitor
Table 2 Expression of potent biomarkers in a panel of non-small cell lung cancer cell lines
Name Type ALDH EpCAM CD133/2 CD24 CD38
A549 Adenocarcinoma + + + + +
H460 Large-cell + + + + -
H661 Large-cell ± + + - -
H520 Squamous cell carcinoma + + + + -
H596 Squamous cell carcinoma - + + + -
SW-900 Squamous cell carcinoma + + ± + +
SK-MES Squamous cell carcinoma ± + + - -
H292 Mucoepidermoid pulmonary carcinoma + + ± + -
Figure 2 Expression of the EpCAM (CD326) in eight non-small cell lung carcinoma cell lines as measured by flow cytometry. IgG was
used as control.
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The authentication of the cell lines were confirmed by
the perfect match between the cell lines data and the
parental cell lines released by American Type Culture
Collection [23].
Expression of ALDHA1
We first analyzed the expression of aldehyde dehydro-
genase in eight NSCLC cell lines using Aldefluor Assay
Kit (Stem Cell Technologies, Vancouver, BC) that is op-
timized for interaction with human ALDH 1A1. As a
negative control, cells were treated with DEAB, an in-
hibitor of aldehyde dehydrogenase. Our analysis showed
that half of the panel expresses a high level of ALDHA1Figure 3 Flow cytometric analysis of CD133/2 in non-small cell lung cfrom 15.3% in SW-900, 34.4% in H520, 42.5% in H292,
and 60.4% in A549. In the other four cell lines (H596,
H661, SK-MES, and H460) expression was not detected
or the level was very low (Figure 1). Table 2 summarizes
the results of ALDH and all other markers that follow.
Expression of EpCAM (CD326)
We next examined the expression of epithelial cell adhe-
sion molecule (EpCam) in the eight cell lines (Figure 2).
All the lung cancer cell lines express EpCam. However,
no specific expression pattern was observed among these
NSCLC based on their histology. For example, large cell
carcinoma cell lines H520 and H460 display one of the
highest and lowest expression among the lung panel with asarcinoma cell lines.
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cell carcinoma cell lines express as high as 85.8% in
H520 to 12.5 and 12.6% in H596 and SW900, respectively.Expression of CD133
All NSCLC cell lines used in this study express a low
level of CD133. The highest level was observed in A549
adenocarcinoma cell line with 10% and the lowest below
2% in SW-900 and H292 cells. The rest of the cell lines
has an expression of CD133 from 3.3% in SK-MES, 3.7%
in H460, 4.0% in H661, 6.0% in H520, and 7.6% in H596
(Figure 3).Expression of CD24 and CD38
With the exception of H661 and SK-MES cells that
apparently do not express a detectable level of CD24
by flow cytometry, the expression of CD24 is very high
in the other six cell lines (Figure 4). The lowest level
was observed in H596 with 34.3% and the other cell
lines are all above 73% and close to 100% in H292 a
mucoepidermoid carcinoma cell line. In contrast the
expression of CD38 is predominantly low to absent in
the majority of the cell lines with the exception of A549,
63.0%, SW-900, 42.8%, and SK-MES, 35.1% (Figure 4).Figure 4 Flow cytometry analysis of the expression of CD24 and CD3To validate the results of flow cytometry analysis, we
extracted RNA from all the cell lines and performed a
quantitative real-time PCR on the samples. As shown
in Figure 5, the RNA expressions were perfectly matched
with the flow cytometry results. We did not observe any
RNA expression for CD24 in H661 and SK-MES cell
lines, and no quantifiable CD38 RNA expression was seen
in the lung cancer cell lines that were CD38-/low by flow
cytometry.
Summary of the gene expression within the cell line panel
Tables 2 and 3 present an overall summary of the results
in order to provide an easy reference. Table 2 displays
the expression of the genes among the individual cell
lines and Table 3 summarizes the percentage of the genes
as potent prognostic and biomarkers for NSCLC.
Discussion and conclusions
In this study we provide a thorough analysis of five
biomarkers of NSCLC in a panel of eight cell lines re-
presenting different types of NSCLC. Approximately 80
percent of all lung cancers are classified as non-small cell,
which is further classified into three sub-types based
on their morphology and physiological characteristics:



















Figure 5 Analysis of CD24 and CD38 expression by quantitative RT-PCR in non-small cell lung carcinoma cell lines.
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adenocarcinoma accounts for approximately 40%, followed
by squamous cell carcinoma with 25-30%, and large-cell
carcinoma with 10-15% [29].
The majority of information available on NSCLC is
based on the available cell lines. Fortunately, scientists
have access to a collection of over 200 lung cancer cell
lines for their research and this has led to more than
9000 citations on the disease [30]. The results obtained
from this extensive research indicate that there is a high
percentage of genomic similarities between lung cancer
cell lines and the tumor they have been isolated from
that provides a cushion of trust for the ongoing research
and the results obtained from the cell lines [30]. We are
therefore confident that our findings deliver robust and
reliable results that could be clinically significant for the
prognosis of NSCLC patients.
A previous report on the NCI60 tumor cell line panel
indicates that the expression of individual markers or
combination of markers was varied among a wide range
of cell lines including lung cancers [31]. One significant
difference with our results, however, lies in the nature of
the two panels. The NCI60 panel consists of 60 diverseTable 3 An overall signature of non-small cell lung cancer
cell line panel and NSCLC tumor initiating cells*
Types Signature %
Large cells ALDH+/CD38-/low/CD133+/EpCAM+ 100






* Excluding adenocarcinoma (insufficient data).human cancer cell lines widely used as a screening tool
for drug discovery and representing nine distinct tumor
types: leukemia, colon, lung, central nervous system, renal,
melanoma, ovarian, breast and prostate [32], while our
panel consists of eight cell lines specifically targeting a
single malignancy, i.e., NSCLC. Our results not only
confirm the presence of the variation in the expression
seen among the 60 cell lines but extend the conclusion
that indeed this heterogeneity and variation also exist at
specific tumor derived cell lines and the three subtypes
of NSCLC.
Our research shows that EpCAM is upregulated in
all NSCLC cell lines. This is not surprising as it has been
speculated elsewhere that proliferation, self-renewal,
and invasiveness of these cells may be facilitated by
the upregulation of EpCAM, leading to its use as a tar-
get of immunotherapy and treatment of human carcin-
oma [15,16].
Detecting EpCAM in circulating tumor cells has pro-
voked considerable interest in cancer therapy and accord-
ingly Food Drug Administration has set the standard for
enriching circulatory tumor cells to capture and measur-
ing the expression of EpCAM in circulating tumor cells
using a magnetic ferrofluid [33]. But since EpCAM is
also expressed heterogeneously in normal epithelial and
in primary cells, combination therapy seems more ap-
propriate for patients. Recently it has also reported that
selected markers including EpCAM have been found to
be present at high levels in the primary tumors while
the level of expression was found to be low or non-
detectable in normal lymph nodes or peripheral blood
of NSCLC patients [34].
Our results also confirm an elevated level of activity of
the ALDH in seven out of eight NSCLC cell lines where
75% of squamous cell carcinoma and all the large cells
are positive for the enzyme.
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to be one of the most representative markers of tumor
initiating cells and in various tumors such as glioblastoma
and colorectal [17,18]. CD133 is also a marker of inter-
est in circulatory tumor cells in malignancies including
NSCLC [35]. In our study, although the entire lung can-
cer cell line panel expresses a low level of CD133/2, we
do not see any indication that the level of expression
could be an indicative of a prognostic marker in NSCLC.
We further looked at CD24 and CD38 cell surface pro-
teins in the panel. CD24 is a potential biomarker of tumors
[36] and the expression of this glycosylphosphatidylinositol-
anchored receptor is upregulated in some of the can-
cers and in NSCLC is consistently associated with
progression and metastasis of the tumors [37]. Our
interest to investigate CD38 in NSCLC started with a
previous finding in our laboratory that the enzyme is
overexpressed in cancer stem cells isolated from a NSCLC
cell line [23].
We observed an upregulation of CD24 in over 75% of
NSCLC patients and for the first time we present con-
clusive data that 75% of the lung cell lines panel virtually
do not express CD38. Previously we had also shown by
immunofluorescence that the expression of CD38 is
downregulated and CD24 upregulated in human lung
cancer H460 cell line, one of the cell lines in current
study [23]. To our knowledge this is the first report im-
plicating an association between CD38 and NSCLC. Since
a major function of CD38 is the regulation of intercellular
calcium, then the absence or downregulation of the
enzyme in lung cancer cell lines may indicate the
disruption of intercellular calcium pathways in this
disease [25,38]. If combined with CD24, 50% of the
NSCLC cell lines have a CD24+/CD38-/low phenotype
that may qualify this phenotype as a new signature of
NSCLC. Also of interest is the finding that all the
CD24+/CD38-/low cells are CD133, and EpCAM posi-
tive. We strongly suggest a larger scale prospective
study to validate these new diagnostic biomarkers and
their correlation with non-small cell lung cancer
patient’s survival.
Availability of supporting data
The data set supporting the results of the present study
is present within the article.
Competing interests
The authors declare no conflict of interests.
Acknowledgements
The authors thank Dr. David Murray for his valuable comments and editing
and Tony Li for his technical assistance. This work was partially supported by
NCI grant R44CA096025 (HF).
Received: 4 April 2013 Accepted: 31 July 2013
Published: 5 October 2013References
1. Cagle PT, Chirieac LR: Advances in treatment of lung cancer with
targeted therapy. Arch Pathol Lab Med 2012, 136:504–509.
2. Woodward RM, Brown ML, Stewart ST, Cronin KA, Cutler DM: The value
of medical interventions for lung cancer in the elderly: results from
SEER-CMHSF. Cancer 2007, 110:2511–2518.
3. Cipriano LE, Romanus D, Earle CC, Neville BA, Halpern EF, Gazelle GS,
McMahon PM: Lung cancer treatment costs, including patient
responsibility, by disease stage and treatment modality, 1992 to 2003.
Value Health 2011, 14:41–52.
4. Liloglou T, Bediaga NG, Brown BR, Field JK, Davies MP: Epigenetic
biomarkers in lung cancer. Cancer Lett 2012. Apr 27. [Epub ahead of print].
5. Kristiansen G, Schlüns K, Yongwei Y, Denkert C, Dietel M, Petersen I: CD24 is
an independent prognostic marker of survival in nonsmall cell lung
cancer patients. Br J Cancer 2003, 88:231–236.
6. Spiro SG, Tanner NT, Silvestri GA, Janes SM, Lim E, Vansteenkiste JF, Pirker R:
Lung cancer: progress in diagnosis, staging and therapy. Respirology 2010,
15:44–50.
7. Chen HY, Yu SL, Li KC, Yang PC: Biomarkers and transcriptome profiling of
lung cancer. Respirology 2012, 17:620–626.
8. Leng S, Do K, Yingling CM, Picchi MA, Wolf HJ, Kennedy TC, Feser WJ, Baron
AE, Franklin WA, Brock MV, Herman JG, Baylin SB, Byers T, Stidley CA, Belinsky
SA: Defining a gene promoter methylation signature in sputum for lung
cancer risk assessment. Clin Cancer Res 2012, 18:3387–3395.
9. Gámez-Pozo A, Sánchez-Navarro I, Calvo E, Agulló-Ortuño MT, López-Vacas R,
Díaz E, Camafeita E, Nistal M, Madero R, Espinosa E, López JA, Fresno Vara JÁ:
MIF proteins are identified as non-small cell lung cancer biomarkers by
label-free proteomics. PLoS One 2012, 7:e33752.
10. Moreb JS, Zucali JR, Ostmark B, Benson NA: Heterogeneity of aldehyde
dehydrogenase expression in lung cancer cell lines is revealed by
Aldefluor flow cytometry-based assay. Cytometry B Clin Cytom 2007,
72:281–289.
11. Vasiliou V, Pappa A, Petersen DR: Role of aldehyde dehydrogenases in
endogenous and xenobiotic metabolism. Chem Biol Interact 2000,
129:1–19.
12. Moreb JS, Baker HV, Chang LJ, Amaya M, Lopez MC, Ostmark B, Chou W:
ALDH isozymes downregulation affects cell growth, cell motility and
gene expression in lung cancer cells. Mol Cancer 2008, 7:87.
13. Ucar D, Cogle CR, Zucali JR, Ostmark B, Scott EW, Zori R, Gray BA, Moreb JS:
Aldehyde dehydrogenase activity as a functional marker for lung cancer.
Chem Biol Interact 2009, 178:48–55.
14. Pak MG, Shin DH, Lee CH, Lee MK: Significance of EpCAM and TROP2
expression in non-small cell lung cancer. World J Surg Oncol 2012, 6:10–53.
15. van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, Rots MG:
EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis
2010, 31:1913–1921.
16. Munz M, Baeuerle PA, Gires O: The emerging role of EpCAM in cancer and
stem cell signaling. Cancer Res 2009, 69:5627–5629.
17. Akunuru S, James Zhai Q, Zheng Y: Non-small cell lung cancer stem/
progenitor cells are enriched in multiple distinct phenotypic
subpopulations and exhibit plasticity. Cell Death Dis 2012, 3:e352.
18. Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M, Zabinski RF:
CD133/prominin-1 is a potential therapeutic target for antibody-drug
conjugates in hepatocellular and gastric cancers. Br J Cancer 2008, 99:100–109.
19. Woo T, Okudela K, Mitsui H, Yazawa T, Ogawa N, Tajiri M, Yamamoto T, Rino Y,
Kitamura H, Masuda M: Prognostic value of CD133 expression in stage I lung
adenocarcinomas. Int J Clin Exp Pathol 2010, 4:32–42.
20. Kristiansen G, Sammar M, Altevogt P: Tumour biological aspects of CD24,
a mucin-like adhesion molecule. J Mol Histol 2004, 35:255–262.
21. Karimi-Busheri F, Rasouli-Nia A, Mackey JR, Weinfeld M: Senescence evasion
by MCF-7 human breast tumor-initiating cells. Breast Cancer Res 2010, 2:R31.
22. Karimi-Busheri F, Zadorozhny V, Shawler DL, Fakhrai H: The stability of breast
cancer progenitor cells during cryopreservation: maintenance of
proliferation, self-renewal, and senescence characteristics. Cryobiology 2010,
60:308–314.
23. Karimi-Busheri F, Zadorozhny V, Li T, Lin H, Shawler DL, Fakhrai H: Pivotal role of
CD38 biomarker in combination with CD24, EpCAM, and ALDH for
identification of H460 derived lung cancer stem cells. J Stem Cells 2011, 6:9–20.
24. Karimi-Busheri F, Zadorozhny V, Carrier E, Fakhrai H: Molecular integrity and
global gene expression of breast and lung cancer stem cells under
long-term storage and recovery. Cell Tissue Bank 2013, 14:175–186.
Karimi-Busheri et al. Multidisciplinary Respiratory Medicine 2013, 8:65 Page 9 of 9
http://www.mrmjournal.com/content/8/1/6525. Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N: CD38 and
chronic lymphocytic leukemia: a decade later. Blood 2011, 118:3470–3478.
26. Hamblin TJ: CD38: what is it there for? Blood 2003, 102:1939–1940.
27. Jawad M, Yu N, Seedhouse CH, Tandon K, Russell NH, Pallis M: Targeting of
CD34 + CD38- cells using Gemtuzumab Ozogamicin (Mylotarg) in
combination with Tipifarnib (Zarnestra) in Acute Myeloid Leukaemia.
BMC Cancer 2012, 12:431.
28. Dürig J, Naschar M, Schmücker U, Renzing-Köhler K, Hölter T, Hüttmann A,
Dührsen U: CD38 expression is an important prognostic marker in
chronic lymphocytic leukaemia. Leukemia 2002, 16:30–35.
29. Sugarbaker DJ, Dasilva MC: Diagnostic workup of lung cancer. Surg Oncol
Clin N Am 2011, 20:667–679.
30. Gazdar AF, Girard L, Lockwood WW, Lam WL, Minna JD: Lung cancer cell
lines as tools for biomedical discovery and research. J Natl Cancer Inst
2010, 102:1310–1321.
31. Stuelten CH, Mertins SD, Busch JI, Gowens M, Scudiero DA, Burkett MW,
Hite KM, Alley M, Hollingshead M, Shoemaker RH, Niederhuber JE: Complex
display of putative tumor stem cell markers in the NCI60 tumor cell line
panel. Stem Cells 2010, 28:649–660.
32. Shoemaker RH: The NCI60 human tumour cell line anticancer drug
screen. Nat Rev Cancer 2006, 6:813–823.
33. Ni J, Cozzi PJ, Duan W, Shigdar S, Graham PH, John KH, Li Y: Role of the
EpCAM (CD326) in prostate cancer metastasis and progression.
Cancer Metastasis Rev 2012, 31:779–791.
34. Nordgård O, Singh G, Solberg S, Jørgensen L, Halvorsen AR, Smaaland R,
Brustugun OT, Helland A: Novel molecular tumor cell markers in regional
lymph nodes and blood samples from patients undergoing surgery for
non-small cell lung cancer. PLoS One 2013, 8:e62153.
35. Vroling L, Lind JS, de Haas RR, Verheul HM, van Hinsbergh VW, Broxterman HJ,
Smit EF: CD133+ circulating haematopoietic progenitor cells predict for
response to sorafenib plus erlotinib in non-small cell lung cancer patients.
Br J Cancer 2010, 102:268–275.
36. Mierke CT, Bretz N, Altevogt P: Contractile forces contribute to increased
glycosylphosphatidylinositol-anchored receptor CD24-facilitated cancer
cell invasion. J Biol Chem 2011, 286:34858–34871.
37. Lee HJ, Choe G, Jheon S, Sung SW, Lee CT, Chung JH: CD24, a novel
cancer biomarker, predicting disease-free survival of non-small cell lung
carcinomas: a retrospective study of prognostic factor analysis from the
viewpoint of forthcoming (seventh) new TNM classification. J Thorac
Oncol 2010, 5:649–657.
38. Deaglio S, Vaisitti T, Serra S, Audrito V, Bologna C, DAQZAZ’Arena G,
Laurenti L, Gottardi D, Malavasi F: CD38 in chronic lymphocytic leukemia:
from bench to bedside? Mini Rev Med Chem 2011, 11:503–507.
doi:10.1186/2049-6958-8-65
Cite this article as: Karimi-Busheri et al.: CD24+/CD38- as new prognostic
marker for non-small cell lung cancer. Multidisciplinary Respiratory
Medicine 2013 8:65.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
